Stanley H. Korman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Stanley H. Korman has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
Alisa Gutman
Department of Clinical Biochemistry, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
14 shared publicationsA. Gutman
Department of Clinical Biochemistry Hadassah – Hebrew University Medical Center Jerusalem Israel
3 shared publicationsAvihu Boneh
3 shared publications- Brage Storstein Andresen
Department of Biochemistry and Molecular Biology, University of Southern Denmark, Odense, Denmark
3 shared publications Avraham Zeharia
Day Hospitalization Unit, Schneider Children's Medical Center of Israel, Sackler School of Medicine, Tel Aviv University, Petach Tikvah, Israel
2 shared publicationsCornelis Jakobs
Department of Clinical Chemistry ,VU University Medical Center, Amsterdam, The Netherlands
2 shared publications
Latest Publications
- 30 May 2007
- Published by Springer Nature in Journal of Human Genetics
- Vol. 52 (7) , 599-606
A novel PEX12 mutation identified as the cause of a peroxisomal biogenesis disorder with mild clinical phenotype, mild biochemical abnormalities in fibroblasts and a mosaic catalase immunofluorescence pattern, even at 40 °C
Journal of Human Genetics, official journal of the Japan Society of Human Genetics, publishes original articles and reviews on all aspects of human genetics, including medical genetics and genomics
- 30 May 2007
- Published by Springer Nature in Journal of Human Genetics
- Vol. 52 (7) , 599-606
A novel PEX12 mutation identified as the cause of a peroxisomal biogenesis disorder with mild clinical phenotype, mild biochemical abnormalities in fibroblasts and a mosaic catalase immunofluorescence pattern, even at 40 °C
Journal of Human Genetics, official journal of the Japan Society of Human Genetics, publishes original articles and reviews on all aspects of human genetics, including medical genetics and genomics
- 1 March 2007
- Published by Elsevier in European Journal of Paediatric Neurology
- Vol. 11 (2) , 81-89
Glutaric aciduria type 1: Clinical, biochemical and molecular findings in patients from Israel
- 1 March 2007
- Published by Elsevier in European Journal of Paediatric Neurology
- Vol. 11 (2) , 81-89
Glutaric aciduria type 1: Clinical, biochemical and molecular findings in patients from Israel
- 31 December 2006
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 89 (4) , 332-338
A novel SLC25A20 splicing mutation in patients of different ethnic origin with neonatally lethal carnitine-acylcarnitine translocase (CACT) deficiency
- 31 December 2006
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 89 (4) , 332-338
A novel SLC25A20 splicing mutation in patients of different ethnic origin with neonatally lethal carnitine-acylcarnitine translocase (CACT) deficiency
- 1 December 2006
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 89 (4) , 289-299
Inborn errors of isoleucine degradation: A review
- 1 December 2006
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 89 (4) , 289-299
Inborn errors of isoleucine degradation: A review
- 17 August 2006
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 29 (5) , 620-626
TAT gene mutation analysis in three Palestinian kindreds with oculocutaneous tyrosinaemia type II; characterization of a silent exonic transversion that causes complete missplicing by exon 11 skipping
Deficiency of the hepatic cytosolic enzyme tyrosine aminotransferase (TAT) causes marked hypertyrosinaemia leading to painful palmoplantar hyperkeratoses, pseudodendritic keratitis and variable mental retardation (oculocutaneous tyrosinaemia type II or Richner–Hanhart syndrome). Parents may therefore seek prenatal diagnosis, but this is not possible by biochemical assays as tyrosine does not accumulate in amniotic fluid and TAT is not expressed in chorionic villi or amniocytes. Molecular analysis is therefore the only possible approach for prenatal diagnosis and carrier detection. To this end, we sought TAT gene mutations in 9 tyrosinaemia II patients from three consanguineous Palestinian kindreds. In two kindreds (7 patients), the only potential abnormality identified after sequencing all 12 exons and exon–intron boundaries was homozygosity for a silent, single-nucleotide transversion c.1224G > T (p.T408T) at the last base of exon 11. This was predicted to disrupt the 5′ donor splice site of exon 11 and result in missplicing. However, as TAT is expressed exclusively in liver, patient mRNA could not be obtained for splicing analysis. A minigene approach was therefore used to assess the effect of c.1224G > T on exon 11 splicing. Transfection experiments with wild-type and c.1224G > T mutant minigene constructs demonstrated that c.1224G > T results in complete exon 11 skipping, illustrating the utility of this approach for confirming a putative splicing defect when cDNA is unavailable. Homozygosity for a c.1249C > T (R417X) exon 12 nonsense mutation (previously reported in a French patient) was identified in both patients from the third kindred, enabling successful prenatal diagnosis of an unaffected fetus using chorionic villous tissue.
- 17 August 2006
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 29 (5) , 620-626
TAT gene mutation analysis in three Palestinian kindreds with oculocutaneous tyrosinaemia type II; characterization of a silent exonic transversion that causes complete missplicing by exon 11 skipping
Deficiency of the hepatic cytosolic enzyme tyrosine aminotransferase (TAT) causes marked hypertyrosinaemia leading to painful palmoplantar hyperkeratoses, pseudodendritic keratitis and variable mental retardation (oculocutaneous tyrosinaemia type II or Richner–Hanhart syndrome). Parents may therefore seek prenatal diagnosis, but this is not possible by biochemical assays as tyrosine does not accumulate in amniotic fluid and TAT is not expressed in chorionic villi or amniocytes. Molecular analysis is therefore the only possible approach for prenatal diagnosis and carrier detection. To this end, we sought TAT gene mutations in 9 tyrosinaemia II patients from three consanguineous Palestinian kindreds. In two kindreds (7 patients), the only potential abnormality identified after sequencing all 12 exons and exon–intron boundaries was homozygosity for a silent, single-nucleotide transversion c.1224G > T (p.T408T) at the last base of exon 11. This was predicted to disrupt the 5′ donor splice site of exon 11 and result in missplicing. However, as TAT is expressed exclusively in liver, patient mRNA could not be obtained for splicing analysis. A minigene approach was therefore used to assess the effect of c.1224G > T on exon 11 splicing. Transfection experiments with wild-type and c.1224G > T mutant minigene constructs demonstrated that c.1224G > T results in complete exon 11 skipping, illustrating the utility of this approach for confirming a putative splicing defect when cDNA is unavailable. Homozygosity for a c.1249C > T (R417X) exon 12 nonsense mutation (previously reported in a French patient) was identified in both patients from the third kindred, enabling successful prenatal diagnosis of an unaffected fetus using chorionic villous tissue.
- 10 January 2006
- Published by Wiley in Annals of Neurology
- Vol. 59 (2) , 411-415
Treatment from birth of nonketotic hyperglycinemia due to a novel GLDC mutation
Objective: To determine whether the devastating outcome of neonatal‐onset glycine encephalopathy (NKH) could be improved by instituting treatment immediately at birth rather than after symptoms are already well established.Methods: A newborn with NKH diagnosed prenatally following the neonatal death of a previous affected sibling was treated from birth with oral sodium benzoate (250mg/kg/day) and the NMDA receptor antagonist ketamine (15mg/kg/day) immediately after sampling cord blood and cerebrospinal fluid (CSF) for glycine determination. Glycine cleavage system (CGS) activity was determined in placental tissue. Mutation analysis was performed by sequencing all GLDC, GCSH and AMT exons.Results: CSF glycine (99 μmol/L, reference 3.8–8.0) was already markedly elevated at birth. GCS activity in placental tissue was severely reduced (2.6% of controls). A novel homozygous GLDC c.482A→G(Y161C) missense mutation was identified. Neonatal hypotonia and apnea did not occur but the long‐term outcome was poor, with intractable seizures and severe psychomotor retardation. This contrasts with the favorable outcome with early treatment in variant NKH with mild GCS deficiency (Ann Neuol 2004;56:139–143).Interpretation: Prospective treatment with this regimen can favorably modify the early neonatal course of severe NKH but does not prevent the poor long‐term outcome, suggesting glycine‐induced prenatal injury and/or ongoing postnatal damage. Ann Neurol 2006
- 10 January 2006
- Published by Wiley in Annals of Neurology
- Vol. 59 (2) , 411-415
Treatment from birth of nonketotic hyperglycinemia due to a novel GLDC mutation
Objective: To determine whether the devastating outcome of neonatal‐onset glycine encephalopathy (NKH) could be improved by instituting treatment immediately at birth rather than after symptoms are already well established.Methods: A newborn with NKH diagnosed prenatally following the neonatal death of a previous affected sibling was treated from birth with oral sodium benzoate (250mg/kg/day) and the NMDA receptor antagonist ketamine (15mg/kg/day) immediately after sampling cord blood and cerebrospinal fluid (CSF) for glycine determination. Glycine cleavage system (CGS) activity was determined in placental tissue. Mutation analysis was performed by sequencing all GLDC, GCSH and AMT exons.Results: CSF glycine (99 μmol/L, reference 3.8–8.0) was already markedly elevated at birth. GCS activity in placental tissue was severely reduced (2.6% of controls). A novel homozygous GLDC c.482A→G(Y161C) missense mutation was identified. Neonatal hypotonia and apnea did not occur but the long‐term outcome was poor, with intractable seizures and severe psychomotor retardation. This contrasts with the favorable outcome with early treatment in variant NKH with mild GCS deficiency (Ann Neuol 2004;56:139–143).Interpretation: Prospective treatment with this regimen can favorably modify the early neonatal course of severe NKH but does not prevent the poor long‐term outcome, suggesting glycine‐induced prenatal injury and/or ongoing postnatal damage. Ann Neurol 2006
- 1 November 2005
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 86 (3) , 337-343
Novel metabolic and molecular findings in hepatic carnitine palmitoyltransferase I deficiency
- 1 November 2005
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 86 (3) , 337-343
Novel metabolic and molecular findings in hepatic carnitine palmitoyltransferase I deficiency
- 1 March 2005
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 51 (3) , 610-617
2-Ethylhydracrylic Aciduria in Short/Branched-Chain Acyl-CoA Dehydrogenase Deficiency: Application to Diagnosis and Implications for the R-Pathway of Isoleucine Oxidation
Background: Isolated excretion of 2-methylbutyrylglycine (2-MBG) is the hallmark of short/branched-chain acyl-CoA dehydrogenase deficiency (SBCADD), a recently identified defect in the proximal pathway of l-isoleucine oxidation. SBCADD might be underdiagnosed because detection and recognition of urine acylglycines is problematic. Excretion of 2-ethylhydracrylic acid (2-EHA), an intermediate formed in the normally minor R-pathway of l-isoleucine oxidation, has not previously been described in SBCADD.
- 1 March 2005
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 51 (3) , 610-617
2-Ethylhydracrylic Aciduria in Short/Branched-Chain Acyl-CoA Dehydrogenase Deficiency: Application to Diagnosis and Implications for the R-Pathway of Isoleucine Oxidation
Background: Isolated excretion of 2-methylbutyrylglycine (2-MBG) is the hallmark of short/branched-chain acyl-CoA dehydrogenase deficiency (SBCADD), a recently identified defect in the proximal pathway of l-isoleucine oxidation. SBCADD might be underdiagnosed because detection and recognition of urine acylglycines is problematic. Excretion of 2-ethylhydracrylic acid (2-EHA), an intermediate formed in the normally minor R-pathway of l-isoleucine oxidation, has not previously been described in SBCADD.
- 24 November 2004
- Published by Wiley in Prenatal Diagnosis
- Vol. 24 (11) , 857-860
Prenatal diagnosis for arginase deficiency by second‐trimester fetal erythrocyte arginase assay and first‐trimester ARG1 mutation analysis
Hyperargininemia is a progressive neurometabolic disorder caused by deficiency of hepatic cytosolic arginase I, resulting from mutations in the ARG1 gene. We diagnosed arginase deficiency in a three‐year‐old male child of first‐cousin Palestinian Arab parents. Prenatal diagnosis of an unaffected fetus was achieved in the second trimester of a subsequent pregnancy by cordocentesis and analysis of arginase activity in fetal erythrocytes. ARG1 mutation analysis in the proband revealed homozygosity for a deletion of 10 753 bp extending from the first intron to beyond the poly (A) site of the gene. This is the first gross deletion in the ARG1 gene to be identified and the first mutation to be described in an arginase‐deficient patient of this ethnic origin. The identification of the ARG1 deletion in this family enabled first‐trimester prenatal diagnosis in a subsequent pregnancy by multiplex PCR analysis performed on chorionic villous DNA. Copyright © 2004 John Wiley & Sons, Ltd.
- 24 November 2004
- Published by Wiley in Prenatal Diagnosis
- Vol. 24 (11) , 857-860
Prenatal diagnosis for arginase deficiency by second‐trimester fetal erythrocyte arginase assay and first‐trimester ARG1 mutation analysis
Hyperargininemia is a progressive neurometabolic disorder caused by deficiency of hepatic cytosolic arginase I, resulting from mutations in the ARG1 gene. We diagnosed arginase deficiency in a three‐year‐old male child of first‐cousin Palestinian Arab parents. Prenatal diagnosis of an unaffected fetus was achieved in the second trimester of a subsequent pregnancy by cordocentesis and analysis of arginase activity in fetal erythrocytes. ARG1 mutation analysis in the proband revealed homozygosity for a deletion of 10 753 bp extending from the first intron to beyond the poly (A) site of the gene. This is the first gross deletion in the ARG1 gene to be identified and the first mutation to be described in an arginase‐deficient patient of this ethnic origin. The identification of the ARG1 deletion in this family enabled first‐trimester prenatal diagnosis in a subsequent pregnancy by multiplex PCR analysis performed on chorionic villous DNA. Copyright © 2004 John Wiley & Sons, Ltd.
- 17 October 2004
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 28 (4) , 467-472
Elevated plasma citrulline and arginine due to consumption of Citrullus vulgaris (watermelon)
Summary: A 19‐month‐old girl with developmental delay was found to have moderately elevated plasma citrulline and mildly elevated plasma arginine concentrations. Dietary history revealed that she consumed large quantities of watermelon (Citrullus vulgaris), a fruit containing high free citrulline and arginine concentrations. In order to determine whether the patient's high watermelon intake could account for her elevated plasma citrulline and arginine concentrations, we studied the response of plasma citrulline and arginine to ingestion of watermelon in six healthy adult volunteers. All developed markedly elevated plasma citrulline (mean maximum 593 μmol/L, range 386–1069) and moderately elevated plasma arginine (mean maximum 199 μmol/L, range 128–251). Physicians and laboratory personnel performing metabolic investigations should be aware of watermelon‐induced citrullinaemia. Its hallmarks are elevated plasma citrulline, and to a lesser extent arginine, in the absence of orotic or arginosuccinic aciduria or hyperammonaemia. This phenomenon has implications for the management of patients with urea cycle and related disorders.
- 17 October 2004
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 28 (4) , 467-472
Elevated plasma citrulline and arginine due to consumption of Citrullus vulgaris (watermelon)
Summary: A 19‐month‐old girl with developmental delay was found to have moderately elevated plasma citrulline and mildly elevated plasma arginine concentrations. Dietary history revealed that she consumed large quantities of watermelon (Citrullus vulgaris), a fruit containing high free citrulline and arginine concentrations. In order to determine whether the patient's high watermelon intake could account for her elevated plasma citrulline and arginine concentrations, we studied the response of plasma citrulline and arginine to ingestion of watermelon in six healthy adult volunteers. All developed markedly elevated plasma citrulline (mean maximum 593 μmol/L, range 386–1069) and moderately elevated plasma arginine (mean maximum 199 μmol/L, range 128–251). Physicians and laboratory personnel performing metabolic investigations should be aware of watermelon‐induced citrullinaemia. Its hallmarks are elevated plasma citrulline, and to a lesser extent arginine, in the absence of orotic or arginosuccinic aciduria or hyperammonaemia. This phenomenon has implications for the management of patients with urea cycle and related disorders.